Clinical trials: Cancer (Solid Tumors)
Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
This is a Phase Ib, open-label, multicenter study of HSK41959 tablets in combination with standard therapy in patients with MTAP-deficient advanced solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
- Trial name
- NCT07699757
- Testing
- HSK41959, Sintilimab, Pemetrexed + Cisplatin /Carboplatin
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Advanced Solid Tumor
XTX301 in Patients With Advanced Solid Tumors
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT05684965
- Testing
- XTX301
- Where
- 12 sites in United States
- Volunteers
- 358 people
- Sponsor
- Xilio Development, Inc.
Solid Tumor
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
This is an open-label, Phase 1 dose-escalation study followed by a 2-arm expansion cohort of Oraxol administered in combination with pembrolizumab.
- Trial name
- NCT03588039
- Testing
- Oraxol, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Athenex, Inc.
Solid Tumours
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Study to assess the effect of Itraconazole and Fluconazole on the pharmacokinetics of Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Male Volunteers
- Trial name
- NCT02093728
- Testing
- selumetinib, itraconazole, fluconazole
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Advanced Stage Cancer (Solid Tumor Disease for 4 Patients), Acute Myeloid Leukemia (6 Patients)
Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of…
- Trial name
- NCT03420430
- Testing
- GL-ONC1
- Where
- United States
- Sponsor
- Genelux Corporation
Advanced Solid Tumor, Lymphomas
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
LEE011 is a new oral drug designed to inhibit the activity of an enzyme known as CDK4/6. CDK4/6 is involved in the process that allows both normal and cancer cells to divide and multiply.
- Trial name
- NCT01237236
- Testing
- LEE011
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 156 people
- Sponsor
- Novartis Pharmaceuticals
Gynecologic Cancer
Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer
Dose-dense paclitaxel (Genexol®-PM) once a week in combination with carboplatin every 3 weeks for gynecologic cancer (adult solid tumor): a phase I trial.
- Trial name
- NCT02739529
- Testing
- Genexol-PM
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Solid Tumors
A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors
This is a Phase 1 open-label study and consists of 3 treatment groups (dose levels) . Treatment cycles are 3 weeks in duration. The primary objective of this study is to determine the recommended phase two dose (RPTD) of…
- Trial name
- NCT01617928
- Testing
- veliparib (ABT-888), carboplatin, paclitaxel
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Solid Tumors
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
This is a two-part trial in patients with squamous non-small cell lung cancer (NSCLC), platinum (Pt)-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer (TNBC).
- Trial name
- NCT01930292
- Testing
- Part A: Debio 1143, Paclitaxel, Carboplatin
- Where
- 4 sites in France
- Volunteers
- 31 people
- Sponsor
- Debiopharm International SA
Cancer
Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors
The purpose of this study is to determine whether MBP-426 (liposomal oxaliplatin suspension for injection) is safe and effective in the treatment of advanced or metastatic solid tumors.
- Trial name
- NCT00355888
- Testing
- MBP-426
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Mebiopharm Co., Ltd
Metastatic Solid Tumor
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.
- Trial name
- TROPiCS-03 (NCT03964727)
- Testing
- Sacituzumab Govitecan-hziy
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 227 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumor
A Study of LM-24C5 For Advanced Solid Tumors
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
- Trial name
- NCT06187402
- Testing
- LM-24C5
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- LaNova Medicines Limited
Solid Tumors
CetuGEX™: Phase 1 Study in Cancer Patients
This was a prospective, open label, multicenter study evaluating the safety, tolerability and pharmacokinetics of CetuGEX™ after intravenous administration in patients with EGFR positive, locally advanced and/or metastatic solid…
- Trial name
- NCT01222637
- Testing
- CetuGEX™
- Where
- 5 sites in Germany, Italy and 1 more
- Volunteers
- 41 people
- Sponsor
- Glycotope GmbH
Advanced Cancer, Solid Tumors
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
This study is a first-in-human, multicenter, open-label, nonrandomized, dose-escalation trial to be conducted in 2 sequential parts: Part A (Dose Escalation) in subjects with advanced malignancies Part B (Dose Confirmation) in…
- Trial name
- NCT02797795
- Testing
- NEV801
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Neovia Oncology Ltd.
Breast Cancer, Solid Tumor
A Study of TY-302 in Patients With Advanced Solid Tumors
The primary objective of this study is to evaluate the safety and tolerability of TY-302 single and the combination with Tamoxifen in dose-escalation and dose-expansion study.The drugs involved in this study are: TY-302 Tamoxifen
- Trial name
- NCT04433494
- Testing
- TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- TYK Medicines, Inc
Tumors
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Inthis study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with gemcitabine to patients with solid tumours.
- Trial name
- NCT00372437
- Testing
- MGCD0103, Gemcitabine
- Where
- 8 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Mirati Therapeutics Inc.
Advanced Solid Tumors
A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors
This is a first in human phase I , open label study to evaluate the safety and tolerability of GENA 104A16 administered as a single agent by intravenous (IV) once every 2 weeks ( q2w (1 cycle = 2 weeks) in patients with advanced…
- Trial name
- NCT06235541
- Testing
- GENA-104A16
- Where
- South Korea
- Sponsor
- Genome & Company
Malignancies, Lymphoma
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to determine the recommended Phase 2 dose and the maximum tolerated dose.
- Trial name
- NCT00320827
- Testing
- CS-1008 (humanized anti-DR5 antibody)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Advanced Solid Tumor
A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors
Protocol YY-20394-003 is a phase I single arm, open label study. The primary objective is to assess the safety of YY-20394 in subjects with advanced solid tumor.
- Trial name
- NCT04049929
- Testing
- YY-20394
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.